Despite the poor efficacy of PD-1– and PD-L1–targeting immunotherapies in DLBCL (30), our data imply that PD-1 expression on T cells regarding their interaction with B cells is clinically important. The gene discussed is CD274; the disease is diffuse large B-cell lymphoma.